nach oben

Molecular Diagnosis & Therapy

Erschienen in:

01.10.2018 | Review Article

Biomarkers and Pharmacogenomics in Kidney Transplantation

verfasst von: L. E. Crowley, M. Mekki, S. Chand

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

This review is focused on present and future biomarkers, along with pharmacogenomics used in clinical practice for kidney transplantation. It aims to highlight biomarkers that could potentially be used to improve kidney transplant early and long-term graft survival, but also potentially patient co-morbidity. Future directions for improving outcomes are discussed, which include immune tolerance and personalising immunosuppression regimens.

Taylor D, Robb M, Casula A, Caskey F. UK Renal Registry 19th Annual Report: Chapter 11 Centre variation in access to kidney transplantation (2010–2015). Nephron. 2017;137(Suppl 1):259–68.PubMedCrossRef

Perkins D, Verma M, Park KJ. Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol. 2011;33(2):211–8.PubMedPubMedCentralCrossRef

Sigdel TK, Gao Y, He J, Wang A, Nicora CD, Fillmore TL, et al. Mining the human urine proteome for monitoring renal transplant injury. Kidney Int. 2016;89(6):1244–52.PubMedPubMedCentralCrossRef

Moes DJAR, Press RR, Ackaert O, Ploeger BA, Bemelman FJ, Diack C, et al. Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. Br J Clin Pharmacol. 2016;82(1):227–37.PubMedPubMedCentralCrossRef

Reese PP, Hall IE, Weng FL, Schroppel B, Doshi MD, Hasz RD, et al. Associations between deceased-donor urine injury biomarkers and kidney transplant outcomes. J Am Soc Nephrol. 2016;27(5):1534–43.PubMedCrossRef

Hollmen ME, Kyllonen LE, Inkinen KA, Lalla MLT, Merenmies J, Salmela KT. Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study. Crit Care. 2011;15(3):R121.PubMedPubMedCentralCrossRef

Koo TY, Jeong JC, Lee Y, Ko K-P, Lee K-B, Lee S, et al. Pre-transplant evaluation of donor urinary biomarkers can predict reduced graft function after deceased donor kidney transplantation. Medicine (Baltimore). 2016;95(11):e3076.PubMedPubMedCentralCrossRef

Bhangoo RS, Hall IE, Reese PP, Parikh CR. Deceased-donor kidney perfusate and urine biomarkers for kidney allograft outcomes: a systematic review. Nephrol Dial Transplant. 2012;27(8):3305–14.PubMedPubMedCentralCrossRef

van den Akker EK, Hesselink DA, Manintveld OC, IJzermans JNM, de Bruijn RWF, Dor FJMF. Neutrophil gelatinase-associated lipocalin, but not kidney injury marker 1, correlates with duration of delayed graft function. Eur Surg Res. 2015;55(4):319–27.PubMedCrossRef

10.

van Smaalen TC, Beurskens DMH, Hoogland ERP, Winkens B, Christiaans MHL, Reutelingsperger CP, et al. Presence of cytotoxic extracellular histones in machine perfusate of donation after circulatory death kidneys. Transplantation. 2017;101(4):e93–101.PubMedCrossRef

11.

van Balkom BWM, Gremmels H, Ooms LSS, Toorop RJ, Dor FJMF, de Jong OG, et al. Proteins in preservation fluid as predictors of delayed graft function in kidneys from donors after circulatory death. Clin J Am Soc Nephrol. 2017;12(5):817–24.PubMedPubMedCentralCrossRef

12.

Patel K, Nath J, Hodson J, Inston N, Ready A. Outcomes of donation after circulatory death kidneys undergoing hypothermic machine perfusion following static cold storage: a UK population-based cohort study. Am J Transplant. 2017. https://doi.org/10.1111/ajt.14587.CrossRefPubMedPubMedCentral

13.

Chen C-C, Chapman WC, Hanto DW. Ischemia-reperfusion injury in kidney transplantation. Front Biosci (Elite Ed). 2015;7:117–34.PubMed

14.

Muhlberger I, Perco P, Fechete R, Mayer B, Oberbauer R. Biomarkers in renal transplantation ischemia reperfusion injury. Transplantation. 2009;88(3 Suppl):S14–9.PubMedCrossRef

15.

Thomas RAB, Czopek A, Bellamy COC, McNally SJ, Kluth DC, Marson LP. Hemin preconditioning upregulates heme oxygenase-1 in deceased donor renal transplant recipients: a randomized, controlled, phase IIB trial. Transplantation. 2016;100(1):176–83.PubMedCrossRef

16.

Alvarez S, Suazo C, Boltansky A, Ursu M, Carvajal D, Innocenti G, et al. Urinary exosomes as a source of kidney dysfunction biomarker in renal transplantation. Transplant Proc. 2013;45(10):3719–23.PubMedCrossRef

17.

Malyszko J, Lukaszyk E, Glowinska I, Durlik M. Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. Sci Rep. 2015;5:11684.PubMedPubMedCentralCrossRef

18.

Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol. 2010;21(1):189–97.PubMedPubMedCentralCrossRef

19.

Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6(7):1639–45.PubMedCrossRef

20.

Lee EY, Kim MS, Park Y, Kim H-S. Serum neutrophil gelatinase-associated lipocalin and interleukin-18 as predictive biomarkers for delayed graft function after kidney transplantation. J Clin Lab Anal. 2012;26(4):295–301.PubMedCrossRef

21.

Cui L-Y, Zhu X, Yang S, Zhou J-S, Zhang H-X, Liu L, et al. Prognostic value of levels of urine neutrophil gelatinase-associated lipocalin and interleukin-18 in patients with delayed graft function after kidney transplantation. Transplant Proc. 2015;47(10):2846–51.PubMedCrossRef

22.

Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem. 2014;51(Pt 3):335–51.PubMedPubMedCentralCrossRef

23.

Malyszko J, Koc-Zorawska E, Malyszko JS, Mysliwiec M. Kidney injury molecule-1 correlates with kidney function in renal allograft recipients. Transplant Proc. 2010;42(10):3957–9.PubMedCrossRef

24.

Yadav B, Prasad N, Agrawal V, Jaiswal A, Agrawal V, Rai M, et al. Urinary Kidney injury molecule-1 can predict delayed graft function in living donor renal allograft recipients. Nephrology (Carlton). 2015;20(11):801–6.CrossRef

25.

Schroppel B, Kruger B, Walsh L, Yeung M, Harris S, Garrison K, et al. Tubular expression of KIM-1 does not predict delayed function after transplantation. J Am Soc Nephrol. 2010;21(3):536–42.PubMedPubMedCentralCrossRef

26.

Pajek J, Skoberne A, Sosteric K, Adlesic B, Leskosek B, Bucar Pajek M, et al. Non-inferiority of creatinine excretion rate to urinary L-FABP and NGAL as predictors of early renal allograft function. BMC Nephrol. 2014;15:117.PubMedPubMedCentralCrossRef

27.

Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.PubMedPubMedCentralCrossRef

28.

Wilflingseder J, Sunzenauer J, Toronyi E, Heinzel A, Kainz A, Mayer B, et al. Molecular pathogenesis of post-transplant acute kidney injury: assessment of whole-genome mRNA and miRNA profiles. PLoS One. 2014;9(8):e104164.PubMedPubMedCentralCrossRef

29.

Wang Y, Tao Y. Research progress on regulatory T cells in acute kidney injury. J Immunol Res. 2015;2015:174164.PubMedPubMedCentral

30.

Nguyen M-TJP, Fryml E, Sahakian SK, Liu S, Michel RP, Lipman ML, et al. Pretransplantation recipient regulatory T cell suppressive function predicts delayed and slow graft function after kidney transplantation. Transplantation. 2014;98(7):745–53.PubMedCrossRef

31.

Nguyen M-TJP, Fryml E, Sahakian SK, Liu S, Cantarovich M, Lipman M, et al. Pretransplant recipient circulating CD4+ CD127lo/- tumor necrosis factor receptor 2+ regulatory T Cells: a surrogate of regulatory T cell-suppressive function and predictor of delayed and slow graft function after kidney transplantation. Transplantation. 2016;100(2):314–24.PubMedCrossRef

32.

Erpicum P, Hanssen O, Weekers L, Lovinfosse P, Meunier P, Tshibanda L, et al. Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients, part II: omics analyses of urine and blood samples. Clin Kidney J. 2017;10(1):106–15.PubMed

33.

Ong S, Mannon RB. Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine. Transplant Rev (Orlando). 2015;29(2):60–7.CrossRef

34.

Jackson JA, Kim EJ, Begley B, Cheeseman J, Harden T, Perez SD, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11(10):2228–34.PubMedPubMedCentralCrossRef

35.

Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013;13(10):2634–44.PubMedPubMedCentralCrossRef

36.

Rabant M, Amrouche L, Lebreton X, Aulagnon F, Benon A, Sauvaget V, et al. Urinary C–X–C motif chemokine 10 independently improves the noninvasive diagnosis of antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2015;26(11):2840–51.PubMedPubMedCentralCrossRef

37.

Blydt-Hansen TD, Sharma A, Gibson IW, Mandal R, Wishart DS. Urinary metabolomics for noninvasive detection of borderline and acute T cell-mediated rejection in children after kidney transplantation. Am J Transplant. 2014;14(10):2339–49.PubMedCrossRef

38.

Ding R, Li B, Muthukumar T, Dadhania D, Medeiros M, Hartono C, et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation. 2003;75(8):1307–12.PubMedCrossRef

39.

Tatapudi RR, Muthukumar T, Dadhania D, Ding R, Li B, Sharma VK, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004;65(6):2390–7.PubMedCrossRef

40.

Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013;369(1):20–31.PubMedPubMedCentralCrossRef

41.

Zhang R. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol. 2017. https://doi.org/10.2215/CJN.00700117.CrossRefPubMedPubMedCentral

42.

Aubert O, Loupy A, Hidalgo L, Duong van Huyen J-P, Higgins S, Viglietti D, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28(6):1912–23.PubMedPubMedCentralCrossRef

43.

Gourishankar S, Leduc R, Connett J, Cecka JM, Cosio F, Fieberg A, et al. Pathological and clinical characterization of the “troubled transplant”: data from the DeKAF study. Am J Transplant. 2010;10(2):324–30.PubMedPubMedCentralCrossRef

44.

Israni A, Leduc R, Holmes J, Jacobson PA, Lamba V, Guan W, et al. Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation. 2010;90(12):1401–8.PubMedPubMedCentralCrossRef

45.

Oetting WS, Schladt DP, Leduc RE, Jacobson PA, Guan W, Matas AJ, et al. Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort. Transpl Int. 2011;24(12):1231–8.PubMedPubMedCentralCrossRef

46.

Kurian SM, Williams AN, Gelbart T, Campbell D, Mondala TS, Head SR, et al. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. Am J Transplant. 2014;14(5):1164–72.PubMedPubMedCentralCrossRef

47.

Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, et al. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med. 2014;11(11):e1001759.PubMedPubMedCentralCrossRef

48.

Shen-Orr SS, Tibshirani R, Khatri P, Bodian DL, Staedtler F, Perry NM, et al. Cell type-specific gene expression differences in complex tissues. Nat Methods. 2010;7(4):287–9.PubMedPubMedCentralCrossRef

49.

Li L, Khatri P, Sigdel TK, Tran T, Ying L, Vitalone MJ, et al. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant. 2012;12(10):2710–8.PubMedPubMedCentralCrossRef

50.

Crespo E, Roedder S, Sigdel T, Hsieh S-C, Luque S, Cruzado JM, et al. Molecular and functional noninvasive immune monitoring in the ESCAPE study for prediction of subclinical renal allograft rejection. Transplantation. 2017;101(6):1400–9.PubMedCrossRef

51.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293–307.PubMedPubMedCentralCrossRef

52.

Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, et al. Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. Am J Transplant. 2017;17(11):2851–62.PubMedCrossRef

53.

Furness PN, Taub N. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int. 2001;60(5):1998–2012.PubMedCrossRef

54.

Hu X, Bai Y, Li S, Zeng K, Xu L, Liu Z, et al. Donor or recipient TNF-A -308G/A polymorphism and acute rejection of renal allograft: a meta-analysis. Transpl Immunol. 2011;25(1):61–71.PubMedCrossRef

55.

Dhaouadi T, Sfar I, Bardi R, Jendoubi-Ayed S, Abdallah TB, Ayed K, et al. Cytokine gene polymorphisms in kidney transplantation. Transplant Proc. 2013;45(6):2152–7.PubMedCrossRef

56.

Sanchez-Fructuoso AI, Perez-Flores I, Valero R, Moreno MA, Fernandez-Arquero M, Urcelay E, et al. The polymorphism -308G/A of tumor necrosis factor-alpha gene modulates the effect of immunosuppressive treatment in first kidney transplant subjects who suffer an acute rejection. J Immunol Res. 2016;2016:2197595.PubMedPubMedCentralCrossRef

57.

Hu Q, Tian H, Wu Q, Li J, Cheng X, Liao P. Interleukin-10-1082 G/a polymorphism and acute renal graft rejection: a meta-analysis. Ren Fail. 2016;38(1):57–64.PubMedCrossRef

58.

Xiong J, Wang Y, Zhang Y, Nie L, Wang D, Huang Y, et al. Lack of association between interleukin-10 gene polymorphisms and graft rejection risk in kidney transplantation recipients: a meta-analysis. PLoS One. 2015;10(6):e0127540.PubMedPubMedCentralCrossRef

59.

Park J-Y, Park MH, Park H, Ha J, Kim SJ, Ahn C. TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans. Tissue Antigens. 2004;64(6):660–6.PubMedCrossRef

60.

Kocierz M, Siekiera U, Kolonko A, Karkoszka H, Chudek J, Cierpka L, et al. 174G/C interleukin-6 gene polymorphism and the risk of transplanted kidney failure or graft loss during a 5-year follow-up period. Tissue Antigens. 2011;77(4):283–90.PubMedCrossRef

61.

Elens L, Bouamar R, Shuker N, Hesselink DA, van Gelder T, van Schaik RHN. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol. 2014;77(4):715–28.PubMedPubMedCentralCrossRef

62.

Schroppel B, Legendre C. Delayed kidney graft function: from mechanism to translation. Kidney Int. 2014;86(2):251–8.PubMedCrossRef

63.

Chapman JR. Do protocol transplant biopsies improve kidney transplant outcomes? Curr Opin Nephrol Hypertens. 2012;21(6):580–6.PubMedCrossRef

64.

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, et al. Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation. Ther Drug Monit. 2016;38(Suppl 1):S1–20.PubMedCrossRef

65.

Danger R, Sawitzki B, Brouard S. Immune monitoring in renal transplantation: the search for biomarkers. Eur J Immunol. 2016;46(12):2695–704.PubMedCrossRef

66.

Chand S, McKnight AJ, Borrows R. Genetic polymorphisms and kidney transplant outcomes. Curr Opin Nephrol Hypertens. 2014;23(6):605–10.PubMedCrossRef

67.

Suzuki Y, Itoh H, Fujioka T, Sato F, Kawasaki K, Sato Y, et al. Association of plasma concentration of 4beta-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. Drug Metab Dispos. 2014;42(1):105–10.PubMedCrossRef

68.

Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, et al. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Clin Ther. 2013;35(11):1762–9.PubMedCrossRef

69.

Genvigir FDV, Salgado PC, Felipe CR, Luo EYF, Alves C, Cerda A, et al. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenet Genomics. 2016;26(10):462–72.PubMedCrossRef

70.

Li D, Teng R, Zhu H, Fang Y. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2013;51(6):466–74.PubMedCrossRef

71.

Niioka T, Kagaya H, Miura M, Numakura K, Saito M, Inoue T, et al. Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol. 2013;69(9):1659–65.PubMedCrossRef

72.

Elens L, Capron A, van Schaik RHN, De Meyer M, De Pauw L, Eddour DC, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608–16.PubMed

73.

Pallet N, Jannot A-S, El Bahri M, Etienne I, Buchler M, de Ligny BH, et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am J Transplant. 2015;15(3):800–5.PubMedCrossRef

74.

Suarez-Kurtz G, Vargens DD, Santoro AB, Hutz MH, de Moraes ME, Pena SDJ, et al. Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population. PLoS One. 2014;9(1):e83472.PubMedPubMedCentralCrossRef

75.

Madsen MJ, Bergmann TK, Brosen K, Thiesson HC. The pharmacogenetics of tacrolimus in corticosteroid-sparse pediatric and adult kidney transplant recipients. Drugs R D. 2017;17(2):279–86.PubMedPubMedCentralCrossRef

76.

Mostafa-Hedeab G, Saber-Ayad MM, Latif IA, Elkashab SO, Elshaboney TH, Mostafa MI, et al. Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. J Clin Pharmacol. 2013;53(8):827–33.PubMedCrossRef

77.

Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52(9):751–62.PubMedPubMedCentralCrossRef

78.

Vafadari R, Bouamar R, Hesselink DA, Kraaijeveld R, van Schaik RHN, Weimar W, et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit. 2013;35(4):459–65.PubMedCrossRef

79.

Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19–24.PubMedPubMedCentralCrossRef

80.

Pallet N, Etienne I, Buchler M, Bailly E, Hurault de Ligny B, Choukroun G, et al. Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype. Am J Transplant. 2016;16(9):2670–5.PubMedCrossRef

81.

Shuker N, Bouamar R, van Schaik RHN, Clahsen-van Groningen MC, Damman J, Baan CC, et al. A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2016;16(7):2085–96.PubMedCrossRef

82.

Boughton O, Borgulya G, Cecconi M, Fredericks S, Moreton-Clack M, MacPhee IAM. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br J Clin Pharmacol. 2013;76(3):425–31.PubMedPubMedCentralCrossRef

83.

Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui C-H, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387–91.PubMedPubMedCentralCrossRef

84.

Orlando G, Hematti P, Stratta RJ, Burke GW, Di Cocco P, Pisani F, et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg. 2010;252(6):915–28.PubMedPubMedCentralCrossRef

85.

Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1848–61.PubMedPubMedCentralCrossRef

86.

Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1836–47.PubMedPubMedCentralCrossRef

87.

Lozano JJ, Pallier A, Martinez-Llordella M, Danger R, Lopez M, Giral M, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant. 2011;11(9):1916–26.PubMedCrossRef

88.

Viklicky O, Krystufkova E, Brabcova I, Sekerkova A, Wohlfahrt P, Hribova P, et al. B-cell-related biomarkers of tolerance are up-regulated in rejection-free kidney transplant recipients. Transplantation. 2013;95(1):148–54.PubMedCrossRef

89.

Carreras-Planella L, Borras FE, Franquesa M. Tolerance in kidney transplantation: what is on the B side? Mediators Inflamm. 2016;2016:8491956.PubMedPubMedCentralCrossRef

90.

Rebollo-Mesa I, Nova-Lamperti E, Mobillo P, Runglall M, Christakoudi S, Norris S, et al. Biomarkers of tolerance in kidney transplantation: are we predicting tolerance or response to immunosuppressive treatment? Am J Transplant. 2016;16(12):3443–57.PubMedPubMedCentralCrossRef

91.

Krepsova E, Tycova I, Sekerkova A, Wohlfahrt P, Hruba P, Striz I, et al. Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance. BMC Nephrol. 2015;16:146.PubMedPubMedCentralCrossRef

92.

Viklicky O, Hribova P, Brabcova I. Molecular markers of rejection and tolerance: lessons from clinical research. Nephrol Dial Transplant. 2013;28(11):2701–8.PubMedCrossRef

93.

Wekerle T, Segev D, Lechler R, Oberbauer R. Strategies for long-term preservation of kidney graft function. Lancet. 2017;389(10084):2152–62.PubMedCrossRef

94.

Chhabra AY, Leventhal J, Merchak AR, Ildstad S. HSCT-based approaches for tolerance induction in renal transplant. Transplantation. 2017;101(11):2682–90.PubMedCrossRef

95.

Vanikar AV, Trivedi HL, Thakkar UG. Six years’ experience of tolerance induction in renal transplantation using stem cell therapy. Clin Immunol. 2018;187:10–4.PubMedCrossRef

96.

Behnam Sani K, Sawitzki B. Immune monitoring as prerequisite for transplantation tolerance trials. Clin Exp Immunol. 2017;189(2):158–70.PubMedPubMedCentralCrossRef

97.

Leventhal JR, Mathew JM, Salomon DR, Kurian SM, Friedewald JJ, Gallon L, et al. Nonchimeric HLA-identical renal transplant tolerance: regulatory immunophenotypic/genomic biomarkers. Am J Transplant. 2016;16(1):221–34.PubMedCrossRef

98.

Fujiwara T, Teruta S, Tsudaka S, Ota K, Matsuda H. Clinical courses of graft failure caused by chronic allograft dysfunction in kidney transplantation. Transplant Proc. 2017;49(1):49–52.PubMedCrossRef

99.

Vanhove T, Goldschmeding R, Kuypers D. Kidney fibrosis: origins and interventions. Transplantation. 2017;101(4):713–26.PubMedCrossRef

100.

Stegall MD, Cornell LD, Park WD, Smith BH, Cosio FG. Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury. Am J Transplant. 2017;18(1):180–8.PubMedCrossRef

101.

Khalkhali HR, Ghafari A, Hajizadeh E, Kazemnejad A. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction. Exp Clin Transplant. 2010;8(4):277–82.PubMed

102.

Menon MC, Keung KL, Murphy B, O’Connell PJ. The use of genomics and pathway analysis in our understanding and prediction of clinical renal transplant injury. Transplantation. 2016;100(7):1405–14.PubMedPubMedCentralCrossRef

103.

Nakorchevsky A, Hewel JA, Kurian SM, Mondala TS, Campbell D, Head SR, et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol. 2010;21(2):362–73.PubMedPubMedCentralCrossRef

104.

Banon-Maneus E, Diekmann F, Carrascal M, Quintana LF, Moya-Rull D, Bescos M, et al. Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation. 2010;89(5):548–58.PubMedCrossRef

105.

Quintana LF, Sole-Gonzalez A, Kalko SG, Banon-Maneus E, Sole M, Diekmann F, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol. 2009;20(2):428–35.PubMedPubMedCentralCrossRef

106.

Sigdel TK, Salomonis N, Nicora CD, Ryu S, He J, Dinh V, et al. The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics. Mol Cell Proteom. 2014;13(2):621–31.CrossRef

107.

Tetaz R, Trocme C, Roustit M, Pinel N, Bayle F, Toussaint B, et al. Predictive diagnostic of chronic allograft dysfunction using urinary proteomics analysis. Ann Transplant. 2012;17(3):52–60.PubMedCrossRef

108.

Boor P, Floege J. Renal allograft fibrosis: biology and therapeutic targets. Am J Transplant. 2015;15(4):863–86.PubMedCrossRef

109.

Kiberd BA, Miller A, Martin S, Tennankore KK. De novo donor-specific human leukocyte antigen antibody screening in kidney transplant recipients after the first year posttransplantation: a medical decision analysis. Am J Transplant. 2016;16(11):3212–9.PubMedCrossRef

110.

Cioni M, Nocera A, Innocente A, Tagliamacco A, Trivelli A, Basso S, et al. De novo donor-specific HLA antibodies developing early or late after transplant are associated with the same risk of graft damage and loss in nonsensitized kidney recipients. J Immunol Res. 2017;2017:1747030.PubMedPubMedCentralCrossRef

111.

Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95(3):410–7.PubMedCrossRef

112.

Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol. 2015;26(2):457–67.PubMedCrossRef

113.

Lachmann N, Schonemann C. The differential pathogenicity of HLA antibodies: what a large cross-sectional study can tell us. Clin Transpl 2013;377–84.

114.

Maluf DG, Dumur CI, Suh JL, Scian MJ, King AL, Cathro H, et al. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int. 2014;85(2):439–49.PubMedCrossRef

115.

Zununi Vahed S, Omidi Y, Ardalan M, Samadi N. Dysregulation of urinary miR-21 and miR-200b associated with interstitial fibrosis and tubular atrophy (IFTA) in renal transplant recipients. Clin Biochem. 2017;50(1–2):32–9.PubMedCrossRef

116.

Zununi Vahed S, Poursadegh Zonouzi A, Mahmoodpoor F, Samadi N, Ardalan M, Omidi Y. Circulating miR-150, miR-192, miR-200b, and miR-423-3p as non-invasive biomarkers of chronic allograft dysfunction. Arch Med Res. 2017;48(1):96–104.PubMedCrossRef

117.

O’Connell PJ, Zhang W, Menon MC, Yi Z, Schroppel B, Gallon L, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet. 2016;388(10048):983–93.PubMedPubMedCentralCrossRef

118.

Nikolova PN, Ivanova MI, Mihailova SM, Myhailova AP, Baltadjieva DN, Simeonov PL, et al. Cytokine gene polymorphism in kidney transplantation–impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome. Transpl Immunol. 2008;18(4):344–8.PubMedCrossRef

119.

Breulmann B, Bantis C, Siekierka M, Blume C, Aker S, Kuhr N, et al. Influence of cytokine genes polymorphisms on long-term outcome in renal transplantation. Clin Transplant. 2007;21(5):615–21.PubMedCrossRef

120.

Liu K, Liu X, Gu S, Sun Q, Wang Y, Meng J, et al. Association between TGFB1 genetic polymorphisms and chronic allograft dysfunction: a systematic review and meta-analysis. Oncotarget. 2017;8(37):62463–9.PubMedPubMedCentral

121.

Inaba A, Clatworthy MR. Novel immunotherapeutic strategies to target alloantibody-producing B and plasma cells in transplantation. Curr Opin Organ Transplant. 2016;21(4):419–26.PubMedCrossRef

122.

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535–46.PubMedCrossRef

123.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374(4):333–43.PubMedCrossRef

Titel: Biomarkers and Pharmacogenomics in Kidney Transplantation
verfasst von: L. E. Crowley
M. Mekki
S. Chand
Publikationsdatum: 01.10.2018
Verlag: Springer International Publishing
Erschienen in: Molecular Diagnosis & Therapy / Ausgabe 5/2018
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI: https://doi.org/10.1007/s40291-018-0349-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Validation Strategy for Ultrasensitive Mutation Detection

Cell-Free eccDNAs: A New Type of Nucleic Acid Component for Liquid Biopsy?

Molecular Detection of Streptococcus pyogenes by Strand Invasion Based Amplification Assay

The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma

Alzheimer’s Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing